title: Gene therapy for sickle cell disease.
abstract: BACKGROUND
  Sickle cell disease encompasses a group of genetic disorders characterized by the presence of at least one hemoglobin S (Hb S) allele, and a second abnormal allele that could allow abnormal hemoglobin polymerisation leading to a symptomatic disorder.Autosomal recessive disorders (such as sickle cell disease) are good candidates for gene therapy because a normal phenotype can be restored in diseased cells with only a single normal copy of the mutant gene.
  
  
  OBJECTIVE
  The objectives of this review are:- to determine whether gene therapy can improve survival and prevent symptoms and complications associated with sickle cell disease;- to examine the risks of gene therapy against the potential long-term gain for people with sickle cell disease.
  
  
  METHODS
  We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, which comprises of references identified from comprehensive electronic database searches and searching relevant journals and abstract books of conference proceedings.Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 05 March 2010.
  
  
  METHODS
  All randomised or quasi-randomised clinical trials (including any relevant phase 1, 2 or 3 trials) of gene therapy for all individuals with sickle cell disease, regardless of age or setting.
  
  
  METHODS
  No trials of gene therapy for sickle cell disease were found.
  
  
  RESULTS
  No trials of gene therapy for sickle cell disease were reported.
  
  
  CONCLUSIONS
  No randomised or quasi-randomised clinical trials of gene therapy for sickle cell disease were reported. Thus, no objective conclusions or recommendations in practice can be made on gene therapy for sickle cell disease. This systematic review has identified the need for well-designed, randomised controlled trials to assess the benefits and risks of gene therapy for sickle cell disease.
authors.affiliation: Lagos University Teaching Hospital, P.O.Box 8893 Marina, Lagos, Nigeria.
authors.forename: Abiola
authors.initials: A
authors.lastname: Olowoyeye
authors.forename: Charles I
authors.initials: CI
authors.lastname: Okwundu
mesh_terms: D000755:Anemia, Sickle Cell / Q000628:therapy*; D015316:Genetic Therapy; D006801:Humans